$MSOS, MAPS NDA, Canopy Growth & Curaleaf TSX Move | Trade To Black
2.1 هزار بار بازدید -
7 ماه پیش
-
Welcome back to the Trade
Welcome back to the Trade To Black Podcast powered by the Benzinga network. For today’s episode we have a jam packed show with tons of updates.
We kick off with significant news from industry giant Canopy Growth. The company has just received full approval for a 10-1 share consolidation to align with Nasdaq regulations. This move aims to bring Canopy's share count down to approximately 70 million, similar to AYR. Shadd Dales, Anthony Varrell and Benjamin A. Smith explore the implications of this.
What happened with MSOS this week? The downturn followed the release of an HHS document that suggested potential movement by the DEA towards descheduling, as interpreted by leaker Shane Pennington. Adding to the intrigue were notable inflows into the MSOS ETF, yet concrete explanations for the market behavior remained elusive. Curaleaf's move to the TSX caused a CSE index imbalance to the DEA's ban on six synthetic cannabinoids and tax loss considerations.
MAPS Public Benefit Corporation (MAPS PBC) has officially submitted an NDA to the FDA. This groundbreaking investigational therapy specifically targets the treatment of post-traumatic stress disorder (PTSD). If approved, it would signify a historic milestone as the first-ever psychedelic therapeutic and protocol sanctioned for PTSD.
Stay tuned for thoughts from a recent conversation with Boris Jordan, where they discuss the details of Curaleaf's strategic move and its broader implications for the landscape of the industry in 2024
To see more videos of the Trade To Black Podcast click the following: Trade To Black Podcast
Subscribe to our newsletter:
https://landing.mailerlite.com/webfor...
Add us on:
Facebook: Facebook: TheDalesReport
Twitter: Twitter: TheDalesReport
Instagram: Instagram: dalesreport
Website: https://thedalesreport.com/
The information provided in this video is for educational purposes only and should not be considered as financial or investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions.
The Dales Report Inc. disclosure policy applies to this video: https://thedalesreport.com/disclosure/
In accordance with an executed agreement between The Dales Report and the aforementioned entity, highlighted either directly or indirectly in the article, The Dales Report has been engaged for a stipulated contractual duration with the purpose of publicly disseminating information pertaining to the aforementioned entity via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for our services involves the receipt of a predefined monetary consideration, which may encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations.
We kick off with significant news from industry giant Canopy Growth. The company has just received full approval for a 10-1 share consolidation to align with Nasdaq regulations. This move aims to bring Canopy's share count down to approximately 70 million, similar to AYR. Shadd Dales, Anthony Varrell and Benjamin A. Smith explore the implications of this.
What happened with MSOS this week? The downturn followed the release of an HHS document that suggested potential movement by the DEA towards descheduling, as interpreted by leaker Shane Pennington. Adding to the intrigue were notable inflows into the MSOS ETF, yet concrete explanations for the market behavior remained elusive. Curaleaf's move to the TSX caused a CSE index imbalance to the DEA's ban on six synthetic cannabinoids and tax loss considerations.
MAPS Public Benefit Corporation (MAPS PBC) has officially submitted an NDA to the FDA. This groundbreaking investigational therapy specifically targets the treatment of post-traumatic stress disorder (PTSD). If approved, it would signify a historic milestone as the first-ever psychedelic therapeutic and protocol sanctioned for PTSD.
Stay tuned for thoughts from a recent conversation with Boris Jordan, where they discuss the details of Curaleaf's strategic move and its broader implications for the landscape of the industry in 2024
To see more videos of the Trade To Black Podcast click the following: Trade To Black Podcast
Subscribe to our newsletter:
https://landing.mailerlite.com/webfor...
Add us on:
Facebook: Facebook: TheDalesReport
Twitter: Twitter: TheDalesReport
Instagram: Instagram: dalesreport
Website: https://thedalesreport.com/
The information provided in this video is for educational purposes only and should not be considered as financial or investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions.
The Dales Report Inc. disclosure policy applies to this video: https://thedalesreport.com/disclosure/
In accordance with an executed agreement between The Dales Report and the aforementioned entity, highlighted either directly or indirectly in the article, The Dales Report has been engaged for a stipulated contractual duration with the purpose of publicly disseminating information pertaining to the aforementioned entity via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for our services involves the receipt of a predefined monetary consideration, which may encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations.
7 ماه پیش
در تاریخ 1402/09/23 منتشر شده
است.
2,133
بـار بازدید شده